GleamWall
中文EN

ALGS Aligos Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1799448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY122.2%
TTM net income YoY23.3%
TTM EPS YoY52.3%
Revenue 3-yr CAGR1.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,244.2%
Net margin-1,137.2%
FCF margin—
EBITDA margin-1,223.5%

Returns

ROE-159.5%
ROA-84.5%
ROIC (approx.)-1,147.1%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets76.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.03x
Accruals ratio2.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.83M$0$2.83M$169,000$741,000$965,000$311,000$606,000
R&D expense$18.89M$24.05M$23.35M$17.04M$23.94M$13.98M$14.50M$16.03M
SG&A expense$5.87M$5.62M$6.41M$4.95M$5.17M$5.56M$5.05M$5.16M
Operating income-$21.89M-$1.89M-$26.93M-$21.81M-$28.36M-$18.57M-$19.24M-$20.56M
Pretax income-$21.53M$1.31M-$22.72M-$19.85M-$31.48M-$15.68M$43.13M-$82.12M
Income tax$326,000$2.81M$317,000$30,000$56,000$185,000$43,000$27,000
Net income-$21.86M-$1.50M-$23.04M-$19.88M-$31.54M-$15.86M$43.09M-$82.15M
EBITDA-$21.59M-$1.59M-$26.58M-$21.56M-$28.16M-$18.27M-$19.05M-$20.32M
EPS (basic)-2.09-0.14-2.21—-3.04-1.535.12—
EPS (diluted)-2.09-0.14-2.21—-3.04-1.53-2.11—
Weighted avg. shares (diluted)10.46M10.43M10.40M—10.37M10.35M8.71M—
Banking
Net interest income$200,000$200,000$100,000$600,000$400,000$400,000$800,000$300,000
Balance sheet
Cash & equivalents$31.09M$30.38M$29.98M$18.30M$42.06M$18.77M$73.87M$37.11M
Short-term investments$0$0$24.93M$59.54M$57.15M$104.28M$64.10M$19.94M
Receivables—$27.78M——————
Current assets$34.68M$62.13M$59.63M$82.86M$103.44M$127.94M$143.21M$62.14M
PP&E, net$1.21M$1.33M$1.59M$1.87M$2.04M$2.06M$2.21M$2.36M
Total assets$47.19M$66.33M$64.56M$88.53M$109.76M$134.71M$150.70M$70.09M
Current liabilities$19.60M$28.34M$23.32M$21.23M$21.99M$20.27M$18.95M$21.74M
Total liabilities$35.88M$34.44M$32.77M$34.99M$37.93M$32.84M$34.25M$99.07M
Shareholders' equity$11.31M$31.88M$31.79M$53.55M$71.83M$101.87M$116.44M-$28.97M
Shares outstanding6.25M6.24M6.19M6.18M6.15M6.15M6.11M3.86M
Cash flow statement
Operating cash flow$1.45M-$24.95M-$23.13M-$21.75M-$24.34M-$15.50M-$20.91M-$18.40M
Investing cash flow-$127,000$25.00M$34.93M-$2.02M$47.68M-$39.42M-$44.07M$19.97M
Financing cash flow-$8,000$220,000-$62,000$123,000-$53,000-$177,000$101.74M$97,000
Depreciation & amortization$300,000$300,000$346,000$257,000$200,000$300,000$194,000$241,000
Stock-based compensation$1.28M$1.36M$1.31M$1.46M$1.47M$1.16M$959,000$1.71M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.